EMA Authorised: Emcitate (tiratricol) — Rare Thyroid Therapeutics International AB

View source ↗

Summary

The EMA authorised Emcitate (tiratricol) for treating thyrotoxicosis and certain hereditary neurodegenerative disorders of the nervous system. The product is de…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Neurodegenerative Disorders of the Nervous System
• Thyrotoxicosis

Drugs mentioned

• Emcitate

Snippet

Status: Authorised. Therapeutic area: Thyrotoxicosis;Heredodegenerative Disorders, Nervous System. MAH: Rare Thyroid Therapeutics International AB. Decision date: 12/02/2025. Orphan medicine